Pancreatic Cancer Research

ResearcherNational Cancer Centre JapanActive in the last 2 years

Susumu Hijioka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0394-6876; OpenAlex author ID A5090787337. Sources: OpenAlex.

Their work

Papers
27 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
100
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: none · 2015: none · 2016: 5 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 3 papers · 2023: 3 papers · 2024: 3 papers · 2025: 4 papers · 2026: 3 papers

Papers 27

  1. Tumor Cell Count and Total Cell Count as Surrogate Indicators of Comprehensive Genomic Profiling Success in Pancreatic Cancer Specimens Collected by Endoscopic… First author DOI 10.1002/jhbp.70106↗
  2. KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation for Detection of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006645↗
  3. 6-mm versus 10-mm covered self-expandable metal stents and plastic stents for malignant distal biliary obstruction in resectable or borderline resectable pancr… First author DOI 10.1186/s13063-026-09821-1↗
  4. Deep learning-based automatic detection of pancreatic ductal adenocarcinoma ≤ 2 cm with high-resolution computed tomography: impact of the combination of tumor… Co-author DOI 10.1007/s11604-025-01836-z↗
  5. Platform of single-molecule enzyme activity-based liquid biopsy for detection of pancreatic adenocarcinoma at early stages Co-author DOI 10.1101/2025.08.07.669035↗
  6. Prospective, multicentre trial on preoperative biliary drainage by endoscopic ultrasound-guided hepaticogastrostomy for resectable/borderline resectable pancre… First author DOI 10.1136/bmjopen-2025-106543↗
  7. Third-line S-1 or FOLFOX treatment in advanced pancreatic cancer who received gemcitabine+nab-paclitaxel and nanoliposomal-irinotecan+5-fluorouracil/leucovorin Co-author DOI 10.21203/rs.3.rs-5801148/v1↗
  8. Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. Co-author DOI 10.1007/s00535-023-02072-w↗
  9. Safety of biliary drainage with 6-mm metallic stent for preoperative obstructive jaundice in pancreatic cancer: PURPLE SIX STUDY. First author DOI 10.1111/jgh.16524↗
  10. Study Protocol for a Prospective Self-Controlled Trial on Success in Meeting Comprehensive Genomic Profiling Analysis Criteria for Specimens Obtained by Endosc… First author DOI 10.3390/diseases12080182↗
  11. Clinical features of germline BRCA1/2 or ATM pathogenic variant positive pancreatic cancer in Japan. Co-author DOI 10.1016/j.pan.2023.10.017↗
  12. Efficient and accurate KRAS genotyping using digital PCR combined with melting curve analysis for ctDNA from pancreatic cancer patients. Co-author DOI 10.1038/s41598-023-30131-y↗
  13. Fine-needle biopsy with 19G needle is effective in combination with endoscopic ultrasound-guided tissue acquisition for genomic profiling of unresectable pancr… First author DOI 10.1111/den.14423↗
  14. Proportion of unresectable pancreatic cancer specimens obtained by endoscopic ultrasound-guided tissue acquisition meeting the OncoGuide™ NCC Oncopanel System … First author DOI 10.1007/s00535-022-01926-z↗
  15. The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10147-022-02186-w↗
  16. Study protocol for a multi-institutional prospective surveillance study among kindreds with familial pancreatic cancer and individuals with hereditary pancreat… Co-author DOI 10.1016/j.pan.2022.04.006↗
  17. Conversion surgery only for highly selected patients with unresectable pancreatic cancer: a satisfactory outcome in exchange for a lower resection rate. Co-author DOI 10.1007/s00595-019-01776-y↗
  18. Familial pancreatic cancer: Concept, management and issues. Co-author DOI 10.3748/wjg.v23.i6.935↗
  19. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis … Co-author DOI 10.1016/j.ejca.2015.11.002↗
  20. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Co-author DOI 10.1016/j.pan.2016.04.007↗
  21. Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study. Co-author DOI 10.1016/j.pan.2016.05.007↗
  22. Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000000446↗
  23. Clinical impact of preoperative endoscopic ultrasound-guided fine-needle aspiration for pancreatic ductal adenocarcinoma. Co-author DOI 10.4103/2303-9027.180472↗
  24. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancrea… Co-author DOI 10.1007/s00535-012-0664-2↗
  25. Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma. Co-author DOI 10.3389/fphys.2013.00269↗
  26. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinic… Co-author DOI 10.1007/s00280-012-1822-1↗
  27. Current concept of endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. Co-author DOI 10.1159/000323502↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chigusa Morizane · 12 shared papers, 2017–2026 · strength 1.95
  2. Takuji Okusaka · 10 shared papers, 2022–2026 · strength 1.83
  3. Daiki Yamashige · 6 shared papers, 2023–2026 · strength 1.27
  4. Akihiro Ohba · 6 shared papers, 2022–2025 · strength 0.95
  5. Shota Harai · 5 shared papers, 2022–2026 · strength 0.89
  6. Go Ikeda · 4 shared papers, 2022–2026 · strength 0.70
  7. Kazuo Hara · 10 shared papers, 2011–2026 · strength 0.66
  8. Kotaro Takeshita · 4 shared papers, 2022–2025 · strength 0.60
  9. Shin Yagi · 3 shared papers, 2024–2025 · strength 0.58
  10. Hidetoshi Kitamura · 4 shared papers, 2022–2024 · strength 0.57
  11. Hideki Ueno · 4 shared papers, 2022–2024 · strength 0.57
  12. Yasushi Yatabe · 6 shared papers, 2011–2024 · strength 0.50
  13. Nobuyoshi Hiraoka · 2 shared papers, 2023–2026 · strength 0.41
  14. Shinichi Yachida · 3 shared papers, 2017–2026 · strength 0.41
  15. Nobumasa Mizuno · 9 shared papers, 2011–2017 · strength 0.40
  16. Junji Furuse · 2 shared papers, 2017–2026 · strength 0.38
  17. Makoto Ueno · 2 shared papers, 2017–2026 · strength 0.38
  18. Yusuke Ishida · 2 shared papers, 2024–2025 · strength 0.36
  19. Satoshi Nara · 2 shared papers, 2024–2025 · strength 0.36
  20. Kazufumi Honda · 2 shared papers, 2024–2025 · strength 0.36
  21. Kenji Yamao · 8 shared papers, 2011–2016 · strength 0.36
  22. Nobuhiko Hayashi · 1 shared paper, 2026 · strength 0.33
  23. Ichiro Yasuda · 1 shared paper, 2026 · strength 0.33
  24. Hiroshi Imaoka · 7 shared papers, 2013–2016 · strength 0.33
  25. Keiji Hanada · 3 shared papers, 2012–2026 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.